Can Seres’ SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint
Can Seres’ SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint
Published: 03/03/2025
Published: 03/03/2025
Can Seres’ SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint